Skip to main content

PONVORY (Janssen-Cilag Pty Ltd)

Product name
PONVORY
Date registered
Evaluation commenced
Decision date
Approval time
112 (255 working days)
Active ingredients
ponesimod
Registration type
NCE/NBE
Indication

PONVORY (film-coated tablet) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

Help us improve the Therapeutic Goods Administration site